BACKGROUND: COVID-19 pandemic has impacted the Italian National Health Care system at many different levels, causing a complete reorganization of surgical wards. In this context, our study retrospectively analysed the management strategy for patients with acute cholecystitis. METHODS: We analysed all patients admitted to our Emergency Department for acute cholecystitis between February and April 2020 and we graded each case according to 2018 Tokyo Guidelines. All patients were tested for positivity to SARS-CoV-2 and received an initial conservative treatment. We focused on patients submitted to cholecystostomy during the acute phase of pandemic and their subsequent disease evolution. RESULTS: Thirty-seven patients were admitted for acute cholecystitis (13 grade I, 16 grade II, 8 grade III). According to Tokyo Guidelines (2018), patients were successfully treated with antibiotic only, bedside percutaneous transhepatic gallbladder drainage (PC) and laparoscopic cholecystectomy (LC) in 29.7%, 21.6% and 48.7% of cases respectively. Therapeutic strategy of three out of 8 cases, otherwise fit for surgery, submitted to bedside percutaneous transhepatic gallbladder drainage (37.5%), were directly modified by COVID-19 pandemic: one due to the SARS-CoV-2 positivity, while two others due to unavailability of operating room and intensive care unit for post-operative monitoring respectively. Overall success rate of percutaneous cholecystostomy was of 87.5%. The mean post-procedural hospitalization length was 9 days, and no related adverse events were observed apart from transient parietal bleeding, conservatively treated. Once discharged, two patients required readmission because of acute biliary symptoms. Median time of drainage removal was 43 days and only 50% patients thereafter underwent cholecystectomy. CONCLUSIONS: Percutaneous cholecystostomy has shown to be an effective and safe treatment thus acquiring an increased relevance in the first phase of the pandemic. Nowadays, considering we are forced to live with the SARS-CoV-2 virus, PC should be considered as a virtuous, alternative tool for potentially all COVID-19 positive patients and selectively for negative cases unresponsive to conservative therapy and unfit for surgery.
BACKGROUND:COVID-19 pandemic has impacted the Italian National Health Care system at many different levels, causing a complete reorganization of surgical wards. In this context, our study retrospectively analysed the management strategy for patients with acute cholecystitis. METHODS: We analysed all patients admitted to our Emergency Department for acute cholecystitis between February and April 2020 and we graded each case according to 2018 Tokyo Guidelines. All patients were tested for positivity to SARS-CoV-2 and received an initial conservative treatment. We focused on patients submitted to cholecystostomy during the acute phase of pandemic and their subsequent disease evolution. RESULTS: Thirty-seven patients were admitted for acute cholecystitis (13 grade I, 16 grade II, 8 grade III). According to Tokyo Guidelines (2018), patients were successfully treated with antibiotic only, bedside percutaneous transhepatic gallbladder drainage (PC) and laparoscopic cholecystectomy (LC) in 29.7%, 21.6% and 48.7% of cases respectively. Therapeutic strategy of three out of 8 cases, otherwise fit for surgery, submitted to bedside percutaneous transhepatic gallbladder drainage (37.5%), were directly modified by COVID-19 pandemic: one due to the SARS-CoV-2 positivity, while two others due to unavailability of operating room and intensive care unit for post-operative monitoring respectively. Overall success rate of percutaneous cholecystostomy was of 87.5%. The mean post-procedural hospitalization length was 9 days, and no related adverse events were observed apart from transient parietal bleeding, conservatively treated. Once discharged, two patients required readmission because of acute biliary symptoms. Median time of drainage removal was 43 days and only 50% patients thereafter underwent cholecystectomy. CONCLUSIONS: Percutaneous cholecystostomy has shown to be an effective and safe treatment thus acquiring an increased relevance in the first phase of the pandemic. Nowadays, considering we are forced to live with the SARS-CoV-2 virus, PC should be considered as a virtuous, alternative tool for potentially all COVID-19 positive patients and selectively for negative cases unresponsive to conservative therapy and unfit for surgery.
Authors: L Ansaloni; M Pisano; F Coccolini; A B Peitzmann; A Fingerhut; F Catena; F Agresta; A Allegri; I Bailey; Z J Balogh; C Bendinelli; W Biffl; L Bonavina; G Borzellino; F Brunetti; C C Burlew; G Camapanelli; F C Campanile; M Ceresoli; O Chiara; I Civil; R Coimbra; M De Moya; S Di Saverio; G P Fraga; S Gupta; J Kashuk; M D Kelly; V Khokha; H Jeekel; R Latifi; A Leppaniemi; R V Maier; I Marzi; F Moore; D Piazzalunga; B Sakakushev; M Sartelli; T Scalea; P F Stahel; K Taviloglu; G Tugnoli; S Uraneus; G C Velmahos; I Wani; D G Weber; P Viale; M Sugrue; R Ivatury; Y Kluger; K S Gurusamy; E E Moore Journal: World J Emerg Surg Date: 2016-11-04 Impact factor: 5.469
Authors: N G Mowbray; J Ansell; J Horwood; J Cornish; P Rizkallah; A Parker; P Wall; A Spinelli; J Torkington Journal: Br J Surg Date: 2020-05-03 Impact factor: 6.939
Authors: Ahmet Surek; Sina Ferahman; Eyup Gemici; Ahmet Cem Dural; Turgut Donmez; Mehmet Karabulut Journal: Eur J Trauma Emerg Surg Date: 2020-11-02 Impact factor: 3.693
Authors: Annalisa Gagliano; Pier Giorgio Villani; Francesca M Co'; Anna Manelli; Stefano Paglia; Pietro A G Bisagni; Gabriele M Perotti; Enrico Storti; Massimo Lombardo Journal: Disaster Med Public Health Prep Date: 2020-03-24 Impact factor: 1.385
Authors: Oscar Cano-Valderrama; Xavier Morales; Carlos J Ferrigni; Esteban Martín-Antona; Victor Turrado; Alejandro García; Yolanda Cuñarro-López; Leire Zarain-Obrador; Manuel Duran-Poveda; José M Balibrea; Antonio J Torres Journal: Int J Surg Date: 2020-07-15 Impact factor: 6.071
Authors: Robert Siegel; Sven Hohenstein; Stefan Anders; Martin Strik; Ralf Kuhlen; Andreas Bollmann Journal: J Gastrointest Surg Date: 2022-04-20 Impact factor: 3.267
Authors: Steven L Cochrun; Timothy Finnegan; Grace E Kennedy; Mason Garland; Jayleen M Grams; Abhishek D Parmar Journal: Am J Surg Date: 2022-09-27 Impact factor: 3.125